CMS-D002

Phase 2Small molecule

SShenzhen Kangzhe Biotechnology Co., Ltd.

CMS-D002 is one of 16 small molecule programs targeting Uterine Fibroid. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine FibroidRecruiting

Uterine FibroidPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Uterine Fibroid

#DrugCompanyPhaseTrials

Orilissa

AbbVie

Approved

7 2

Lupron

Sun Pharmaceutical Industries, Inc.

Mifeprex

4 4

Femara

Cytotec

Cyklokapron

1 7

Esbriet

LLegacy Health System

Approved

—8

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—9

Zoladex

TTerSera Therapeutics LLC

Approved

—10

Orgovyx

Sumitomo Pharma America, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Uterine Fibroid

NCT07402369

Clinical

Trials by Indication[1]

Uterine Fibroid1 trial

Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia

Recruiting·SShenzhen Kangzhe Biotechnology Co., Ltd.·Phase 2·NCT07402369·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CMS-D002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CMS-D002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CMS-D002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Kangzhe Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShenzhen Kangzhe Biotechnology Co., Ltd.

CMS-D002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Uterine Fibroid1 trial

References

Drug Info

Quick Facts

Related News